Sugi Predict

Sugi Predict / Compounds / SCHEMBL4742545

SCHEMBL4742545

SCHEMBL4742545

CCOC1C=Cc2ccccc2N1C(=O)O

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.78
▸ LMNA P02545 2/20 0.78
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ ALDH1A1 P00352 2/20 0.45
▸ NPSR1 Q6W5P4 2/20 0.45
▸ MAPK1 P28482 2/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ P2RX4 Q99571 7/20 0.39
▸ P2RX1 P51575 3/20 0.39
▸ P2RX3 P56373 3/20 0.39
▸ P2RX7 Q99572 2/20 0.39
▸ PTBP1 P26599 1/20 0.39
▸ PPARG P37231 1/20 0.37
▸ PPARA Q07869 1/20 0.37
▸ BCHE P06276 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30563642 1.00 SMN1; SMN2 (0.78) SMN1; SMN2LMNAMEN1KMT2AALDH1A1
SCHEMBL7118147 0.89 LMNA (0.62) SMN1; SMN2LMNAMEN1KMT2AALDH1A1
SCHEMBL29367804 0.87 SMN1; SMN2 (1.00) SMN1; SMN2LMNAMEN1KMT2AALDH1A1
SCHEMBL338 0.87 SMN1; SMN2 (1.00) SMN1; SMN2LMNAMEN1KMT2AALDH1A1
SCHEMBL23705539 0.87 SMN1; SMN2 (1.00) SMN1; SMN2LMNAMEN1KMT2AALDH1A1
SCHEMBL23464966 0.87 LMNA (0.76) SMN1; SMN2LMNAMEN1KMT2AALDH1A1
SCHEMBL367474 0.87 SMN1; SMN2 (1.00) SMN1; SMN2LMNAMEN1KMT2AALDH1A1
SCHEMBL11259902 0.87 LMNA (0.76) SMN1; SMN2LMNAMEN1KMT2AALDH1A1
SCHEMBL9188247 0.86 SMN1; SMN2 (0.82) SMN1; SMN2LMNAMEN1KMT2AALDH1A1
SCHEMBL20358130 0.85 SMN1; SMN2 (0.57) SMN1; SMN2LMNAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008101029-A2 USE OF THIAZOLE, OXAZOLE AND IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS XENON PHARMACEUTICALS INC. (CA) 2008-08-21 — — WO claimed
US-11572386-B2 Process for the preparation of linaclotide Auro Peptides Ltd. (IN) 2023-02-07 — — US disclosed
CN-115490751-A Factor D inhibitors 拜奥克里斯特制药公司 2022-12-20 — — CN disclosed
CN-114728076-A MCL-1 inhibitor antibody-drug conjugates and methods of use 诺华股份有限公司 2022-07-08 — — CN disclosed
CN-114728077-A MCL-1 inhibitor antibody-drug conjugates and methods of use 诺华股份有限公司 2022-07-08 — — CN disclosed
CN-109121414-B Benzopyrazole compounds and analogs thereof 拜奥克里斯特制药公司 2022-07-05 — — CN disclosed
CN-114044800-A Aryl, heteroaryl and heterocyclic compounds for the treatment of medical disorders 艾其林医药公司 2022-02-15 — — CN disclosed
CN-111620861-A BCL-XL inhibitory compound having low cell permeability and antibody drug conjugate including the same 艾伯维公司 2020-09-04 — — CN disclosed
CN-111620862-A BCL-XL-inhibitory compounds and antibody drug conjugates including the same 艾伯维公司 2020-09-04 — — CN disclosed
US-10556924-B2 Process for the preparation of pasireotide BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) 2020-02-11 — — US disclosed
EP-0406404-B1 SUBMICRON PARTICLES, PREPARATION AND UTILIZATION IN IMMUNODIAGNOSIS STAGO DIAGNOSTICA (FR) 1994-06-22 — — EP disclosed
US-5175112-A Binding antigens or antibodies to acrylic latex particles, stabilizing by reacting with material which blocks residual active sites DIAGNOSTICA STAGO (FR) 1992-12-29 — — US disclosed
US-5106835-A Hypotensive agents AMERICAN CYANAMID COMPANY (US) 1992-04-21 — — US disclosed
EP-0406404-A1 SUBMICRON PARTICLES, PREPARATION AND UTILIZATION IN IMMUNODIAGNOSIS. STAGO DIAGNOSTICA (FR) 1991-01-09 — — EP disclosed
WO-1990008321-A1 SUBMICRON PARTICLES, PREPARATION AND UTILIZATION IN IMMUNODIAGNOSIS DIAGNOSTICA STAGO (FR) 1990-07-26 — — WO disclosed
EP-0376012-A2 Renin inhibitors AMERICAN CYANAMID COMPANY (US) 1990-07-04 — — EP disclosed
EP-0376040-A2 N-phosphinyl di-and tripeptides as renin inhibitors AMERICAN CYANAMID COMPANY (US) 1990-07-04 — — EP disclosed
US-4927922-A ANTIBIOTICS AMERICAN CYANAMID COMPANY (US) 1990-05-22 — — US disclosed
US-4800199-A CEPHALOSPORINS AMERICAN CYANAMID COMPANY (US) 1989-01-24 — — US disclosed
EP-0257275-A2 Cephalosporin and penicillin derivatives AMERICAN CYANAMID COMPANY (US) 1988-03-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10556924-B2 Process for the preparation of pasireotide SSTR4, SSTR5, PROKR1 SMN1; SMN2 4027/4885LMNA 2684/4885MEN1 590/4885
US-11572386-B2 Process for the preparation of linaclotide LTB4R2, LPAR2, LTA4H SMN1; SMN2 1547/4885LMNA 776/4885MEN1 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.